🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 86150R107
- Market Cap
- Small Cap
- IPO
- 6/19/2019 · $18.00/share
Business: Stoke Therapeutics, Inc. is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. The Company develops antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. The Company believes their proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow them to deliver disease-modifying therapies in a highly precise, durable and controlled manner.
Company Contact
- CEO
- Emiliano Kargieman
- CFO
- Rick Dunn
- Headquarters
- 45 Wiggins Avenue, Bedford, MA 01730
- Phone
- 781-430-8200
- Investor Relations
- Ryan Driver · 781-303-8302 · ir@satellogic.com